Discovery of a mechanism by which epithelial tumours cause developmental delays
(Institute for Research in Biomedicine (IRB Barcelona)) - Conducted on the fly Drosophila, the study shows that tumours caused by chromosomal instability delay entry into the adult phase.- The tumours produce the Upd3 protein (equivalent to human Interleukin-6) to block the production of developmental steroid hormones.- The work of IRB Barcelona's Growth Control and Development laboratory has been published in the journal Current Biology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2021 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Review supports surgical excision for FEA breast lesions
There's enough evidence to support surgical excision of flat epithelial atypia...Read more on AuntMinnie.comRelated Reading: Can MRI-guided breast biopsy evaluate chemo response? Can AI spot breast cancer years before radiologists? Food, housing insecurity tied to breast biopsy delay Image-guided biopsy spots residual breast cancer Surveillance OK for certain type of breast lesion (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 25, 2021 Category: Radiology Source Type: news

Study: Mesothelioma Survival Rates Rise with SMART Protocol
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at the Princess Margaret Cancer Centre in Toronto. Lancet Oncology recently published results of the study, named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. The SMART study involved 96 patients with pleural mesothelioma who were treated in Toronto from 2008 to 2019. All received the intensity-modulated radiotherapy before extrapleural pneumonectomy surgery, an unconventional treatment regimen. Among the...
Source: Asbestos and Mesothelioma News - January 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of standard of c...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company has...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC).Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 29, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Thymoquinone induces apoptosis & DNA damage in 5-Fluorouracil-resistant colorectal cancer
(Impact Journals LLC) Volume 11, Issue 31 from @Oncotarget reported that TQ decreased the expression levels of colorectal stem cell markers CD44 and Epithelial Cell Adhesion Molecule Ep CAM and proliferation marker Ki67 in colonospheres derived from both cell lines and reduced cellular migration and invasion. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2020 Category: Cancer & Oncology Source Type: news

Oncotarget: Induction of phenotypic changes in HER2-postive breast cancer cells
(Impact Journals LLC) The cover for issue 30 of Oncotarget features Figure 4, " RNAseq results demonstrating differences between normal, cancer, and redirected cells, " by Frank-Kamenetskii, et al. which reported that the influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2020 Category: Cancer & Oncology Source Type: news

Trends in treatment, survival among women with advanced ovarian cancer
(JAMA Network) This observational study examined survival rates and the use of chemotherapy before surgery among women with advanced-stage epithelial ovarian cancer in the United States from 2004 to 2016. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 25, 2020 Category: International Medicine & Public Health Source Type: news

How airway cells work together in regeneration and aging
Researchers at theEli and Edythe Broad Center of  Regenerative Medicine and Stem Cell Research at UCLA have identified the process by which stem cells in the airways of the lungs switch between two distinct phases — creating more of themselves and producing mature airway cells — to regenerate lung tissue after an injury.The study, published in Cell Stem Cell, also sheds light on how aging can cause lung regeneration to go awry, which can lead to lung cancer and other diseases.  “There currently are few therapies that target the biology of lung diseases,” said Dr. Brigitte Gomperts,a professor and vice chair of re...
Source: UCLA Newsroom: Health Sciences - July 27, 2020 Category: Universities & Medical Training Source Type: news

More Mesothelioma Cancer Centers Using Tumor Treating Fields
Tumor Treating Fields is one of the newest treatments on the market for pleural mesothelioma cancer patients with metastatic disease. The device is also available to patients with locally advanced cancer who are not candidates for mesothelioma surgery. Clinical trials of the treatment, previously known as NovoTTF-100L, extended the survival of mesothelioma patients by more than six months compared to those receiving only chemotherapy. The device is now called Optune Lua and has been available outside of clinical trials for over a year. More physicians and treatment centers are becoming certified to prescribe the treatmen...
Source: Asbestos and Mesothelioma News - July 21, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

NCI Studying New Mesothelioma Immunotherapy Combination
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the National Cancer I...
Source: Asbestos and Mesothelioma News - July 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Oncotarget: Epigenetic feedback and stochastic partitioning can drive resistance to EMT
(Impact Journals LLC) Oncotarget Volume 11, Issue 27 published " Epigenetic feedback and stochastic partitioning during cell division can drive resistance to EMT " by Jia et al. which reported that Epithelial-mesenchymal transition (EMT) and its reverse process mesenchymal-epithelial transition are central to metastatic aggressiveness and therapy resistance in solid tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Moffitt researchers identify protein that causes epithelial cancers to spread
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in the July issue of Cancer Research, Elsa Flores, Ph.D., and her team discovered a key protein that oscillates its expression through microRNA regulation to facilitate cancer spread to distant organs. This protein is deltaNp63, a member of the p53 family of tumor suppressor genes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2020 Category: International Medicine & Public Health Source Type: news